Hvivo PLC (LON:HVO)‘s stock had its “add” rating restated by investment analysts at Numis Securities Ltd in a research note issued to investors on Thursday. They currently have a GBX 210 ($2.74) price objective on the stock. Numis Securities Ltd’s target price points to a potential upside of 18.31% from the company’s previous close.

Hvivo PLC (LON:HVO) opened at 174.5876 on Thursday. Hvivo PLC has a 12 month low of GBX 167.00 and a 12 month high of GBX 306.50. The company’s market capitalization is GBX 136.27 million. The company has a 50-day moving average price of GBX 180.66 and a 200 day moving average price of GBX 186.26.

In other news, insider Ellertson,Jaime bought 7,801 shares of the company’s stock in a transaction that occurred on Wednesday, August 3rd. The shares were acquired at an average price of GBX 187 ($2.44) per share, with a total value of £14,587.87 ($19,041.73).

Hvivo PLC Company Profile

Hvivo PLC is the United Kingdom-based holding company. The Company is a virology healthcare business that provides clinical services, focused on the Human Challenge Model (HCM) primarily to pharmaceutical companies and biotechnology organizations. The Company has grown and developed the HCM for evidencing the efficiency of antiviral and viral therapeutics in RSV, flu and cold.

Receive News & Ratings for Hvivo PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hvivo PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.